© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Dr Aaron Berger discusses recent advances in treatment and management of patients with nonmetastatic castrate-resistant prostate cancer.
November 18th 2021
Dr Aaron Berger discusses systemic therapy options, treatment selection and monitoring for patients with nonmetastatic castrate-resistant prostate cancer (nmCRPC).
A prostate cancer expert reviews trial design and efficacy data with next-generation androgen receptor inhibitors.
December 2nd 2021
Aaron Berger, MD, discusses adverse events with enzalutamide, apalutamide and darolutamide and their management.
Dr Aaron Berger shares updated safety data on next-generation androgen receptor inhibitors and impact of safety profile on treatment selection in nmCRPC.
December 13th 2021
A prostate cancer expert discusses comorbidities and dose alterations with next-generation androgen receptor inhibitors in nmCRPC.
Dr Aaron Berger comments on quality of life data and the role of patient preference in nmCRPC.
Aaron Berger, MD, shares unmet needs and challenges in managing patients with nmCRPC.
January 2nd 2022
Aaron Berger, MD, discussed updates in the treatment of nonmetastatic castration-resistant prostate cancer.